Dr. James Herrmann, MD
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb) (1991)
- Years since graduation
- 35
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 640
Licensed in Illinois since 1994, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1991Medical school: University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb)
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
IL license 036088497 (first issued 1994; active) -
Dermatopathology Physician
IL license 036088497 (first issued 1994; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Dupage Medical Group LTD (1,322 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 640
- Services billed
- 3,319
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 1,360 | 217 |
| Established patient office or other outpatient visit, 20-29 minutes | 537 | 433 |
| Pathology examination of tissue using a microscope, intermediate complexity | 409 | 214 |
| Destruction of precancer skin growth, 1 growth | 326 | 268 |
| Established patient office or other outpatient visit, 30-39 minutes | 132 | 103 |
| Destruction of skin growth, 1-14 growths | 122 | 105 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 118 | 17 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 73 | 57 |
| Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | 53 | 39 |
| Application of light to destroy precancer skin growth | 50 | 38 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Triamcinolone Acetonide Other prescribers in Wheaton, IL | 70 |
| Fluorouracil Other prescribers in Wheaton, IL | 37 |
| Ketoconazole Other prescribers in Wheaton, IL | 25 |
| Clobetasol Propionate Other prescribers in Wheaton, IL | 20 |
| Hydrocortisone Other prescribers in Wheaton, IL | 17 |
| Doxycycline Monohydrate Other prescribers in Wheaton, IL | 17 |
| Fluocinonide Other prescribers in Wheaton, IL | 16 |
| Cosentyx Unoready Pen (secukinumab) | 14 |
| Doxycycline Hyclate Other prescribers in Wheaton, IL | 14 |
| Alclometasone Dipropionate | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 45 payments worth $18,737 in total to this clinician.
| AbbVie Inc. | $17,778 |
|---|---|
| Novartis Pharmaceuticals Corporation | $494 |
| Galderma Laboratories, L.P. | $253 |
| Genzyme Corporation | $140 |
| Pfizer Inc. | $32.67 |
| Lilly USA, LLC | $23.34 |
| Amgen Inc. | $15.81 |
| Compensation for services other than consulting (speaking, faculty) | $17,550 |
|---|---|
| Food and Beverage | $989 |
| Travel and Lodging | $198 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $4,550 |
| AbbVie Inc. Sep 17, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $3,250 |
| AbbVie Inc. Feb 20, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $3,250 |
| AbbVie Inc. May 1, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $3,250 |
| AbbVie Inc. Aug 4, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $3,250 |
| Novartis Pharmaceuticals Corporation Sep 26, 2025 | Travel and Lodging Rhapsido · Immunology · travel to Chicago, IL · in-kind | $198 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $15,727 in research payments for these studies, mostly to the institutions running them.
- A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
UCB SA · Recruiting · NCT07290036 - M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
AbbVie Inc. - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
AbbVie Inc. · Active, not recruiting · NCT03568318 - A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Contro…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.